Posted by Michael Wonder on 23 Oct 2024
Cothera Bioscience announces FDA fast track designation for clinical program PC-002
14 October 2024 - Cothera Bioscience is pleased to announce that the US FDA has granted fast track designation to its clinical program PC-002, a first in class deubiquitinase inhibitor that induces Myc degradation as well as inhibits survivin at clinically relevant concentrations.
This designation is a testament to the program’s potential to address significant unmet medical needs in the treatment of relapsed or refractory Burkitt lymphoma.
